Does Insurance Cover Wegovy? How to Check and How to Appeal

There is no national answer to this question. Coverage for Wegovy depends on what kind of insurance you have, who your employer contracted with, which state you live in, and in some cases what your BMI is. Two people with the same diagnosis and the same drug can have wildly different answers.

This guide does two things: it shows you how to find your own answer in about fifteen minutes, and it lays out what to do if the answer is no.

Nothing here is medical advice. Whether Wegovy is appropriate for you is a question for your healthcare provider.

Who actually covers Wegovy in 2026?

Start with the landscape, because it tells you how hard to fight.

Employer plans are the most likely to cover it and the most variable. Business Group on Health found 67% of its surveyed large employers covered GLP-1s for weight management in early 2026 [1]. But the same organization reported coverage falling from 72% in 2025 to 60% in 2026 across a broader measure, and Mercer put adoption at 44% among employers with 500 or more employees. Across the whole employer market, roughly one-third cover them.

The pressure is real. In a June 2026 International Foundation of Employee Benefit Plans survey of nearly 300 US employer health plans, GLP-1s accounted for 11.4% of annual claims, up from 6.9% in 2023 [2]. Of employers that do cover the drugs for weight management, only 72% said they were likely to continue in 2027 [1].

ACA Marketplace plans almost never cover them for obesity. An analysis of all 300 carriers offering 2026 Marketplace plans found only 26 cover GLP-1s for obesity treatment, and those plans exist in only nine states: California, Delaware, Georgia, New York, North Dakota, Pennsylvania, Rhode Island, Vermont and West Virginia. All but four of those carriers restrict coverage to people with a BMI of 40 or higher [3].

Medicaid is a state-by-state coin flip for obesity. Federal law requires states to cover semaglutide for approved indications like diabetes, cardiovascular disease and sleep apnea, but lets them choose on weight loss. KFF counted 13 states covering GLP-1s for obesity under fee-for-service as of January 2026: Delaware, Kansas, Massachusetts, Michigan, Minnesota, Missouri, Mississippi, North Carolina, Rhode Island, Tennessee, Utah, Virginia and Wisconsin [4]. That was down from 16 in October 2025, after California, New Hampshire, Pennsylvania and South Carolina dropped coverage.

Massachusetts has since left that list. MassHealth published the change in Pharmacy Facts #271 on March 12, 2026 and stopped paying for drugs used only to treat obesity or overweight effective July 3, 2026, a cut the state said affects about 22,000 people and saves roughly $15 million a year [12][13]. MassHealth still covers GLP-1s for diabetes and for other medically accepted indications, but a new prior authorization is required. On that primary source, 12 state Medicaid programs cover GLP-1s for obesity as of September 2026, pending KFF’s next count.

Medicare is a separate story covered in our Medicare guide. Short version: Part D cannot cover weight-loss drugs, but a temporary program called the Medicare GLP-1 Bridge covers Wegovy for obesity at $50 a month through the end of 2027.

How do you check your own coverage?

Four steps, in order of usefulness.

1. Find your formulary, not just your benefits summary. Every plan publishes a drug list. Search it for “Wegovy” or “semaglutide.” What you are looking for: is it listed at all, what tier is it on, and does it carry a PA (prior authorization), ST (step therapy) or QL (quantity limit) flag?

2. Check whether anti-obesity medications are excluded as a category. This is the single most important question and it is not always answered by the formulary. Some plans exclude the entire class regardless of what is on the drug list. Call member services and ask: “Are anti-obesity medications a covered benefit on my plan?” Get the answer in writing if you can.

3. Use the manufacturer’s coverage tool. Novo Nordisk runs a coverage-check form that will tell you what it can see about your plan [5]. It is a shortcut, not a substitute for your formulary.

4. Ask your prescriber’s office what they have seen. Practices that write a lot of these prescriptions usually know which local plans approve and which do not, and what documentation those plans want.

What does prior authorization usually require?

If your plan covers Wegovy, expect a prior authorization. Among employers that cover GLP-1s for obesity, 90% require prior authorization, 54% require participation in a weight-management program, and 48% apply BMI thresholds or comorbidity requirements beyond the FDA indication [6].

Typical requirements you will see:

• A documented BMI at or above a threshold, often 30, sometimes 35 or 40
• For BMI below 30, at least one weight-related condition
• Documentation of prior attempts at diet and exercise, sometimes with a specific duration
• Sometimes a trial of a cheaper anti-obesity medication first (step therapy)
• Enrollment in a plan-sponsored weight-management program
• A prescription from a specific type of prescriber

Have your provider’s office submit the BMI with a date, the weight-related conditions with diagnosis codes, and a clear narrative of what has been tried before. The completeness of that first submission matters more than anything you do later.

How fast does the plan have to decide?

Timelines are improving. The CMS Interoperability and Prior Authorization Final Rule (CMS-0057-F) takes effect in 2026 and requires affected plans to decide expedited requests within 72 hours and standard requests within 7 calendar days, and to give a specific reason when they deny [7].

That last requirement is more useful than it sounds. A denial that says only “not medically necessary” is almost impossible to rebut. A denial that says “BMI documentation not provided for the 12 months preceding the request” tells you exactly what to fix.

What do you do when you are denied?

Work the process in order. Skipping steps usually resets you.

Step 1: Read the denial letter carefully. It contains the specific reason, your deadline to appeal, and the address or portal for filing. Most plans allow at least 180 days for an internal appeal, but your letter governs [8].

Step 2: Ask for a peer-to-peer review. Your prescriber calls the plan’s medical director directly. This is often faster than a written appeal and can resolve a denial that came from a missing data point rather than a real disagreement.

Step 3: File the internal appeal in writing. Include:

• The denial letter and its reference number
• A letter of medical necessity from your prescriber addressing the exact reason given
• Your documented BMI history with dates
• Diagnosis codes for any weight-related conditions
• Records of previous weight-management attempts, including other medications tried and why they were stopped
• Relevant clinical guidelines or the FDA label language that supports the indication

Write to the reason for denial, not in general. If they said you failed to document a prior therapy trial, the entire appeal should be about that.

Step 4: If the internal appeal fails, request external review. On most plans this is a legal right. An independent reviewer who does not work for your insurer looks at your case, and their decision is binding on the plan. Your denial letter must explain how to request it. Secondary sources put overturn rates in external review at meaningful levels, though we have not found a rigorous published figure specific to GLP-1s, so treat any percentage you see as an estimate [8][9].

Step 5: Ask about a formulary exception. This is a separate track from a medical-necessity appeal. If the plan covers Zepbound but not Wegovy, or the reverse, a formulary exception request asks the plan to cover a non-preferred drug at the preferred cost. Your prescriber usually has to state why the preferred alternative is not appropriate for you.

What if your pharmacy benefit manager changed the rules on you?

This happened to a lot of people. On July 1, 2025 CVS Caremark, the largest US pharmacy benefit manager, made Wegovy the preferred weight-management GLP-1 on its largest commercial template formularies and removed Zepbound, including for patients who were stable on it [10].

Then it reversed. CVS Health announced the change on May 28, 2026: effective June 1, 2026 it removed the new-to-market block on Foundayo (orforglipron) for plans that had approved coverage, and effective October 1, 2026 it added Zepbound back to its commercial formularies as an additional preferred option at the same tier as Wegovy [11]. For participating plans that removes the tier penalty for choosing tirzepatide. CVS said members get the same copay for either product.

If you were switched against your preference, it is worth checking whether your plan adopted the October 2026 change. Not every plan uses the template formulary, and self-funded employers can choose their own.

An important precision point: Wegovy is semaglutide and Zepbound is tirzepatide. They are different molecules made by different companies. A formulary that prefers one is making a cost decision, not a clinical statement that they are interchangeable.

What if the answer is simply no?

Plenty of people land here, and it is not the end of the road.

Novo Nordisk’s self-pay price for Wegovy is $349 a month for the standard pen ($399 for Wegovy HD 7.2 mg) and $149 to $299 for the pill, with a $199 introductory price for the two lowest pen doses on the first two fills through December 31, 2026 (all self-pay prices, verified 2026-09-14 against Novo Nordisk’s own price guide). Those prices are available through NovoCare Pharmacy, most retail pharmacies, GoodRx and TrumpRx.gov. Our cash-price guide walks through the options.

Two things to know before you go that route. First, self-pay dollars do not count toward your deductible or out-of-pocket maximum, and you agree not to submit the claim to your insurer. Second, about 27% of employers now actively steer workers toward direct-to-consumer platforms instead of covering the drug through the plan, and 21% encourage using FSA, HSA or HRA dollars [2]. Ask your benefits team whether either applies to you, since HSA and FSA money is pre-tax and effectively lowers your cost.

A realistic expectation

Coverage for GLP-1s is tightening, not loosening. Employers are adding requirements rather than removing them, Marketplace coverage is shrinking, and several state Medicaid programs have pulled back under budget pressure. At the same time, cash prices have fallen by more than half in two years.

That combination means the most valuable thing you can do is find out quickly and definitively whether you are covered, rather than spending months in limbo. Get the formulary, ask the category question, and if the answer is no, move to comparing the cash options rather than waiting.

Sources

1. GLP-1 Costs Loom Large for Employers — Business Group on Health, 2026-05
2. Employers aren’t expanding coverage of GLP-1 obesity drugs: survey — CNBC, 2026-07-08
3. GLP-1 coverage under ACA plans continues to decline: 6 notes — Becker’s Payer Issues, 2025-12-02
4. Medicaid Coverage of and Spending on GLP-1s — KFF, 2026-01-16
5. Check your Coverage for Wegovy — NovoCare, retrieved 2026-09-14
6. 2026 Employer Health Care Strategy Survey: Executive Summary — Business Group on Health, 2025
7. How to Appeal a Wegovy Denial: 5 Steps — Honest Care, 2026
8. Appealing Wegovy denial: Prior authorization, letters, and tips — Medical News Today, retrieved 2026-09-14
9. GLP-1 considerations for 2026 — Mercer, 2026
10. CVS Caremark to Place Wegovy as Preferred GLP-1 for Weight Loss — Managed Healthcare Executive, 2025
11. CVS Caremark delivers affordability and access to GLP-1 weight management medications with expanded coverage options — CVS Health, 2026-05-28
12. Pharmacy Facts #271: MassHealth Changes to Management of Anti-Obesity Medications — MassHealth, 2026-03-12
13. MassHealth drops GLP-1 coverage for obesity Friday — The Boston Globe, 2026-07-03